Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in Europe
GlobeNewswire
Extended contract now covers a total of 11 European countries
Crossject will receive milestone payments of up to €1..
Extended contract now covers a total of 11 European countries
Crossject will receive milestone payments of up to €1..
The CEPI-funded study will evaluate the safety, tolerability, and immunogenicity of IAVI's single dose Lassa fever vaccine..
*This additional funding comes at the heels of Selux announcing their third FDA 510(k) clearance on their direct from Positive..